Anti-obesity medication explained

Anti-obesity medication or weight loss medications are pharmacological agents that reduce or control excess body fat. These medications alter one of the fundamental processes of the human body, weight regulation, by: reducing appetite and consequently energy intake, increasing energy expenditure, redirecting nutrients from adipose to lean tissue, or interfering with the absorption of calories.^{[1] [2]}

Weight loss drugs have been developed since the early twentieth century, and many have been banned or withdrawn from the market due to adverse effects, including deaths; other drugs proved ineffective. Although many earlier drugs were stimulants such as amphetamines, in the early 2020s, GLP-1 receptor agonists became popular for weight loss.

The medications liraglutide,^[3] naltrexone/bupropion,^[4] orlistat,^[5] semaglutide,^[6] and tirzepatide^[7] are approved by the US Food and Drug Administration (FDA) for weight management in combination with reduced-calorie diet and increased physical activity. As of 2022, no medication has been shown to be as effective at long-term weight reduction as bariatric surgery.

Mechanisms of action

Energy intake

• 5-HT_2C receptor agonists reduce appetite by working on serotonin receptors in a region of the brain called the hypothalamus.^[8] Lorcaserin (Belviq) was FDA approved for weight loss but was withdrawn from the market because a safety clinical trial shows an increased occurrence of cancer.^[9]
• Cannabinoid receptor antagonists were developed to treat obesity because researchers noticed that cannabinoid agonists (such as THC, the main pharmacologically active component of cannabis), increased appetite. However, some drugs in this class such as rimonabant were withdrawn or ceased development to concerns about mental health and suicide. More selective drugs—some are in development that act only in peripheral tissues, not the brain—may be able to achieve this result with fewer adverse effects.^{[10] [11]}
• GLP-1 agonists such as tirzepatide, semaglutide, and liraglutide slow gastric emptying and also have neurologically driven effects on appetite.^[12] It is unknown if GLP-1 agonists or dual/triple agonists of GLP-1 and/or the glucagon or GIP receptors act solely by reducing energy intake or if they also increase energy expenditure.
• Setmelanotide is an agonist of the melanocortin 4 receptor and is used in people with certain rare genetic conditions that cause obesity. It is less effective and not approved for general obesity.^[13]
• Some weight loss drugs act on the neurotransmitters serotonin, dopamine, and norepinephrine to reduce appetite.^[14]

Energy expenditure

• Adrenergic agonists that work on the beta-2 adrenergic receptor increase energy expenditure. Although some such as clenbuterol are used without medical approval for weight loss, none have achieved approval for this indication due to cardiac risks.^[15] The anti-obesity effects of amphetamines, besides acting on the brain to reduce energy intake, are also mediated by the beta-2 adrenergic receptor.^{[16] [14]} Ephedrine (and related compounds that are also active ingredients in ephedra preparations) exert their effects by acting directly and indirectly as adrenergic agonists.^[17]
• The discontinued drug 2,4-dinitrophenol works by increasing energy expenditure by decreasing the efficiency of mitochondria (uncoupling agent). A prodrug of DNP, HU6, has been tested in clinical trials for weight loss and fatty liver disease.^[18]
• Fibroblast growth factor-21 receptor agonists and drugs increasing FGF-21 activity are being investigated for obesity-related diseases; they can increase energy expenditure and several have been tested in humans.^{[19] [20]}
• Thyroid hormones, another early weight loss drug, also raised energy expenditure but ceased to be used for weight loss due to cardiac risks and other adverse effects.^[21] Selective thyromimetics that work on the thyroid hormone receptor beta may be able to exert some of the beneficial thermogenic effects of thyroid hormones with fewer adverse effects, but none have received approval as of 2023.^[22]

Both

• Amylin analogues can both reduce energy intake and increase expenditure and can usefully be combined with leptin analogues for synergistic effect.^{[23] [24]} The dual amylin and calcitonin receptor agonist cagrilintide, in combination with semaglutide, was more effective than semaglutide alone in promoting weight loss in clinical trials.^{[25] [26]}
• Glucagon receptor agonists both reduce energy intake and increase energy expenditure in humans. They can cause hyperglycemia so it is recommended to combine them with a hypoglycemic drug, such as a GLP-1 or GIP receptor agonist.^{[27] [28]}

Other mechanisms

• Bimagrumab, an experimental drug, works by inhibiting the action of myostatin, which limits the size of skeletal muscle. The drug has shown the ability to increase lean mass simultaneously to decreasing fat mass in obese humans, which is beneficial because it preserves or increases energy expenditure while reducing risks associated with excess fat.^[21]
• Orlistat (Xenical) and cetilistat reduce intestinal fat absorption by inhibiting pancreatic lipase, an enzyme that breaks down triglycerides in the intestine. Without this enzyme, triglycerides from the diet are prevented from being hydrolyzed into absorbable free fatty acids and are excreted undigested.^[29] Frequent oily bowel movements steatorrhea is a possible side effect of using Orlistat. Originally available only by prescription, it was approved by the FDA for over-the-counter sale in February 2007.^[30] In May 2010, the U.S. Food and Drug Administration (FDA) approved a revised label for Xenical to include new safety information about rare cases of severe liver injury that have been reported with the use of this medication.^[31] A 2010 phase 2 trial found cetilistat significantly reduced weight and was better tolerated than orlistat.^[32]
• SGLT2 inhibitors cause the loss of glucose in the urine each day and are associated with a modest, sustained weight loss of in people with type 2 diabetes. The weight loss is less than expected due to compensatory increases in energy intake, but is additive when combined with GLP-1 receptor agonists.^[33]

History

The first described attempts at producing weight loss are those of Soranus of Ephesus, a Greek physician, in the second century AD. He prescribed elixirs of laxatives and purgatives, as well as heat, massage, and exercise. This remained the mainstay of treatment for well over a thousand years. It was not until the 1920s and 1930s that new treatments began to appear. Based on its effectiveness for hypothyroidism, thyroid hormone became a popular treatment for obesity in euthyroid people. It had a modest effect but produced the symptoms of hyperthyroidism as a side effect, such as palpitations and difficulty sleeping.^[34] 2,4-Dinitrophenol (DNP) was introduced in 1933; this worked by uncoupling the biological process of oxidative phosphorylation in mitochondria, causing them to produce heat instead of ATP. Overdose caused fatal hyperthermia and DNP also caused cataracts in some users. After the passage of the Food, Drug, and Cosmetic Act in 1938, the FDA banned DNP for human consumption.^[35]

Amphetamines (marketed as Benzedrine) became popular for weight loss during the late 1930s. They worked primarily by suppressing appetite, and had other beneficial effects such as increased alertness. Use of amphetamines increased over the subsequent decades, including Obetrol and culminating in the "rainbow diet pill" regime.^[36] This was a combination of multiple pills, all thought to help with weight loss, taken throughout the day. Typical regimens included stimulants, such as amphetamines, as well as thyroid hormone, diuretics, digitalis, laxatives, and often a barbiturate to suppress the side effects of the stimulants.^[36] In 1967/1968 a number of deaths attributed to diet pills triggered a Senate investigation and the gradual implementation of greater restrictions on the market. While rainbow diet pills were banned in the US in the late 1960s, they reappeared in South America and Europe in the 1980s.^[36] In 1959, phentermine had been FDA approved and fenfluramine in 1973. In the early 1990s two studies found that a combination of the drugs was more effective than either on its own; fen-phen became popular in the United States and had more than 18 million prescriptions in 1996.^[37] Evidence mounted that the combination could cause valvular heart disease in up to 30 percent of those who had taken it, leading to withdrawal of fen-phen and dexfenfluramine from the market in September 1997.^[38]

In the early 2020s, GLP-1 receptor agonists such as semaglutide or tirzepatide became popular for weight loss because they are more effective than earlier drugs, causing a shortage for patients prescribed these medications for type 2 diabetes, their original indication.^{[39] [40]}

Patient population

The United States Food and Drug Administration and the European Medicines Agency have approved weight loss medications for adults with either a body-mass index (BMI) of at least 30, or a body-mass index of at least 27 with at least one weight-related comorbidity. This patient population is considered to have sufficiently high baseline health risks to justify the use of anti-obesity medication.^{[41] [42]}

The American Academy of Pediatrics had not previously supported the use of weight loss medication in adolescents but issued new guidelines in 2023. It now recommends considering the use of weight loss medication in some overweight children aged 12 or older.^[43] The European Medicines Agency has approved semaglutide for children aged 12 or older who have a BMI in the 95 percentile for their age and a weight of at least .^{[44] [42]} However, GLP-1 agonists may not be cost effective in this population.^[45]

Medication

US FDA approved

The US Food and Drug Administration (FDA) approves anti-obesity medications as an adjunctive therapy to diet and exercise for people for whom lifestyle changes do not result in sufficient weight loss. In the United States, semaglutide (Wegovy) is approved by the FDA for chronic weight management.^[46] The FDA guidelines say that a therapy may be approved if it results in weight loss that is statistically significant greater than placebo and generally at least five percent of body weight over six months that comes predominantly from fat mass.^{[21] [47]} Some other prescription weight loss medications are stimulants, which are recommended only for short-term use, and thus are of limited usefulness for patients who may need to reduce weight over months or years.^[48] As of 2022, there is no pathway for approval for drugs that reduce fat mass without 5 percent overall weight loss, even if they significantly improve metabolic health; neither is there one for drugs that help patients maintain weight loss although this can be more challenging than losing weight.^[21]

As of 2022, no medication has been discovered that would equal the effectiveness of bariatric surgery for long-term weight loss and improved health outcomes.^[49]

!Medication Name!Trade name(s)!Mechanism of action!Current FDA Status!placebo-adjusted percent bodyweight lost (highest dose studied)

Semaglutide	Wegovy	GLP-1 receptor agonist	Approved for weight management (chronic)	12%^[50]
Phentermine/topiramate	Qsymia	Phentermine is a substituted amphetamine and topiramate has an unknown mechanism of action	Approved for weight management (short-term) by the FDA but not the European Medicines Agency^[51]	10%^[52] or ^[53]
Naltrexone/bupropion	Contrave		Approved for weight management (chronic) in the US and EU^[54]	5 percent
Liraglutide	Saxenda	GLP-1 receptor agonist	Approved for weight management (chronic)	4 percent^[55]
Gelesis100	Plenity	Oral hydrogel	FDA approved for weight management (chronic) but the American Gastroenterology Association recommends that its use be limited to clinical trials due to lack of evidence.^[56]	2%^[57]
Orlistat	Xenical	Absorption inhibitor	Approved for weight management (chronic)	percentage not provided^[58]
Phentermine		Substituted amphetamine	Approved for weight management (short-term)	^[59]
Methamphetamine	Desoxyn	Substituted amphetamine	Approved for weight management (short-term)
Tirzepatide	Zepbound	Dual GLP-1 receptor agonist and GIP agonist	FDA approved for weight management (chronic);^[60] EMA approval for weight loss is pending^[61]	^[62]

Withdrawn

!Medication Name!Trade name(s)!Mechanism of action!Current FDA Status!placebo-adjusted percent bodyweight lost (highest dose studied)

Lorcaserin	Belviq	5-HT2C receptor agonist	Withdrawn for safety reasons	6.25 percent^[63]
Sibutramine	Meridia	Serotonin–norepinephrine reuptake inhibitor	Withdrawn due to cardiovascular risks^[64] ^[65]	19.7 percent^[66]
Rimonabant	Acomplia, Zimbutli	Cannabinoid receptor antagonist	Withdrawn for safety reasons	^[67]
Fenfluramine	Fintepla, Pondimin	Serotonin releasing agent	Withdrawn for safety reasons	-
Fenfluramine/phentermine (fen-phen)	Pondimin		Withdrawn for safety reasons	13.9 percent^[68]
Dexfenfluramine	Redux	Serotonin releasing agent	Withdrawn for safety reasons	^[69]
2,4-Dinitrophenol		Uncoupling agent	Withdrawn for safety reasons	per patient on average (uncontrolled study)^[70]
Ephedrine		Adrenergic agonist	Approved for asthma^[71]	Average of in a meta-analysis (all dosages)^[72]
ECA stack		Combination of ephedrine and caffeine, sometimes adding aspirin		Around
Ephedra	Plant extract sold as a dietary supplement	Contains ephedrine, an adrenergic agonist	Banned in 2004 for safety reasons	per month more than placebo^[73]
Amphetamine salts	Obetrol		Approved 1960, withdrawn 1973; Adderall was later approved for ADHD and narcolepsy and is still used for those purposes
Phenylpropanolamine	Was an over-the-counter medication ingredient		Withdrawn in 2005 due to risk of hemorragic stroke	^[74]

Never approved

!Medication Name!Trade name(s)!Mechanism of action!Current FDA Status!placebo-adjusted percent bodyweight lost (highest dose studied)

Retatrutide		GLP-1, GIP, and glucagon receptor triple agonist	In clinical trials	24 percent in a Phase II trial^[75]
Exenatide	Byetta	GLP-1 receptor agonist	Approved for type 2 diabetes	^[76]
Cetilistat		Absorption inhibitor	Not approved	^[77]
Tesofensine (NS2330)		Serotonin–norepinephrine–dopamine reuptake inhibitor	Not FDA approved	10.6 percent^[78]
Metformin	Glucophage	Unknown	Approved for type 2 diabetes	5.6 percent^[79]
Cagrilintide		Dual amylin and calcitonin receptor agonist (DACRA)	Not approved	7.8 percent^[80]
Cagrilintide/semaglutide	CagriSema	DACRA/GLP-1 agonist combination	Not approved	15.4 percent after 32 weeks

Safety and side effects

Some anti-obesity medications can have severe, even, lethal side effects, fen-phen being a famous example. Fen-phen was reported through the FDA to cause abnormal echocardiograms, heart valve problems, and rare valvular diseases.^[81] Out of 25 anti-obesity medications withdrawn from the market between 1964 and 2009, 23 acted by altering the functions of chemical neurotransmitters in the brain. The most common side effects of these drugs that led to withdrawals were mental disturbances, cardiac side effects, and drug abuse or drug dependence. Deaths were associated with seven products.^[82] Ephedra was removed from the US market in 2004 over concerns that it raises blood pressure and could lead to strokes and death.^[83]

External links

• • Prescription Medications to Treat Overweight & Obesity US National Institute of Diabetes and Digestive and Kidney Diseases

Notes and References

1. Ryan . Donna H. . Next Generation Antiobesity Medications: Setmelanotide, Semaglutide, Tirzepatide and Bimagrumab: What do They Mean for Clinical Practice? . Journal of Obesity & Metabolic Syndrome . September 2021 . 30 . 3 . 196–208 . 10.7570/jomes21033 . 34518444 . 8526285 . 2508-6235.
2. Jimenez-Munoz . Carlos M. . López . Marta . Albericio . Fernando . Makowski . Kamil . Targeting Energy Expenditure—Drugs for Obesity Treatment . Pharmaceuticals . May 2021 . 14 . 5 . 435 . 10.3390/ph14050435 . 34066399 . 8148206 . 1424-8247 . free .
3. Web site: Saxenda- liraglutide injection, solution . DailyMed .
4. Web site: Contrave extended release- naltrexone hydrochloride and bupropion hydrochloride tablet, extended release . DailyMed .
5. Web site: Xenical- orlistat capsule . DailyMed .
6. Web site: Wegovy- semaglutide injection, solution . DailyMed .
7. Web site: Zepbound- tirzepatide injection, solution . DailyMed .
8. Shukla AP, Kumar RB, Aronne LJ . 2015 . Lorcaserin Hcl for the treatment of obesity . Expert Opinion on Pharmacotherapy . 16 . 16 . 2531–2538 . 10.1517/14656566.2015.1096345 . 26472579 . 44520532.
9. Web site: 19 February 2019 . FDA requests the withdrawal of the weight-loss drug Belviq, Belviq XR (lorcaserin) from the market . live . https://web.archive.org/web/20201220061627/https://www.fda.gov/drugs/fda-drug-safety-podcasts/fda-requests-withdrawal-weight-loss-drug-belviq-belviq-xr-lorcaserin-market#:~:text=On%20February%2013%2C%202020%20FDA,an%20increased%20occurrence%20of%20cancer . 20 December 2020 . 23 December 2020 . U.S. Food and Drug Administration (FDA).
10. Rohbeck . Elisabeth . Eckel . Juergen . Romacho . Tania . Cannabinoid Receptors in Metabolic Regulation and Diabetes . Physiology . March 2021 . 36 . 2 . 102–113 . 10.1152/physiol.00029.2020 . 33595385 . 231943477 .
11. Nguyen . Thuy . Thomas . Brian F. . Zhang . Yanan . Overcoming the psychiatric side effects of the cannabinoid CB1 receptor antagonists: current approaches for therapeutics development . Current Topics in Medicinal Chemistry . 2019 . 19 . 16 . 1418–1435 . 10.2174/1568026619666190708164841 . 31284863 . 6771026 . 1568-0266.
12. Shah M, Vella A . Effects of GLP-1 on appetite and weight . Reviews in Endocrine & Metabolic Disorders . 15 . 3 . 181–187 . September 2014 . 24811133 . 4119845 . 10.1007/s11154-014-9289-5 .
13. Son . Jang Won . Kim . Sungrae . Comprehensive Review of Current and Upcoming Anti-Obesity Drugs . Diabetes & Metabolism Journal . December 2020 . 44 . 6 . 802–818 . 10.4093/dmj.2020.0258 . 33389955 . 7801751 . free .
14. Coulter . Ann A. . Rebello . Candida J. . Greenway . Frank L. . Centrally Acting Drugs for Obesity: Past, Present, andFuture . Drugs . July 2018 . 78 . 11 . 1113–1132 . 10.1007/s40265-018-0946-y . 30014268 . 6095132 . 0012-6667.
15. Kumari . Sweta . Pal . Biplab . Sahu . Sanjeev Kumar . Prabhakar . Pranav Kumar . Tewari . Devesh . Adverse events of clenbuterol among athletes: a systematic review of case reports and case series . International Journal of Legal Medicine . July 2023 . 137 . 4 . 1023–1037 . 10.1007/s00414-023-02996-1 . 37062796 . 258178293 .
16. Morris . Alan . Unravelling novel weight loss mechanisms . Nature Reviews Endocrinology . July 2020 . 16 . 7 . 343 . 10.1038/s41574-020-0374-4 . 32461617 . 218913041 . 1759-5037. free .
17. Munafò . Antonio . Frara . Stefano . Perico . Norberto . Di Mauro . Rosaria . Cortinovis . Monica . Burgaletto . Chiara . Cantarella . Giuseppina . Remuzzi . Giuseppe . Giustina . Andrea . Bernardini . Renato . In search of an ideal drug for safer treatment of obesity: The false promise of pseudoephedrine . Reviews in Endocrine and Metabolic Disorders . December 2021 . 22 . 4 . 1013–1025 . 10.1007/s11154-021-09658-w . 33945051 . 8724077 . 1573-2606.
18. Harrison . Stephen A. . Loomba . Rohit . Dubourg . Julie . Ratziu . Vlad . Noureddin . Mazen . Clinical Trial Landscape in NASH . Clinical Gastroenterology and Hepatology . July 2023 . 21 . 8 . 2001–2014 . 10.1016/j.cgh.2023.03.041. 37059159 . 258115543 .
19. Sonoda . Junichiro . Chen . Mark Z. . Baruch . Amos . FGF21-receptor agonists: an emerging therapeutic class for obesity-related diseases . Hormone Molecular Biology and Clinical Investigation . May 2017 . 30 . 2 . 10.1515/hmbci-2017-0002 . 28525362 . 4420935 . 1868-1891. free .
20. Abdi Beshir . Semira . Ahmed Elnour . Asim . Soorya . Aadith . Parveen Mohamed . Affana . Sir Loon Goh . Sheron . Hussain . Nadia . Al Haddad . Amal H. I. . Hussain . Faizah . Yousif Khidir . Israa . Abdelnassir . Zainab . A narrative review of approved and emerging anti-obesity medications . Saudi Pharmaceutical Journal . October 2023 . 31 . 10 . 101757 . 10.1016/j.jsps.2023.101757 . 37712012 . 10497995 . 1319-0164.
21. Christoffersen . Berit Østergaard . Sanchez-Delgado . Guillermo . John . Linu Mary . Ryan . Donna H. . Raun . Kirsten . Ravussin . Eric . Beyond appetite regulation: Targeting energy expenditure, fat oxidation, and lean mass preservation for sustainable weight loss . Obesity . April 2022 . 30 . 4 . 841–857 . 10.1002/oby.23374 . 35333444 . 9310705 . 1930-7381.
22. Genchi VA, Palma G, Sorice GP, D'Oria R, Caccioppoli C, Marrano N, Biondi G, Caruso I, Cignarelli A, Natalicchio A, Laviola L, Giorgino F, Perrini S . Pharmacological modulation of adaptive thermogenesis: new clues for obesity management? . Journal of Endocrinological Investigation . November 2023 . 46 . 11 . 2213–2236 . 10.1007/s40618-023-02125-0 . 37378828 . 10558388 . 1720-8386.
23. Lutz . T. A. . Gut hormones such as amylin and GLP-1 in the control of eating and energy expenditure . International Journal of Obesity Supplements . December 2016 . 6 . 1 . S15–S21 . 10.1038/ijosup.2016.4 . 28685025 . 5485879 . 2046-2174.
24. Mietlicki-Baase . Elizabeth G. . Amylin-mediated control of glycemia, energy balance, and cognition . Physiology & Behavior . August 2016 . 162 . 130–140 . 10.1016/j.physbeh.2016.02.034 . 26922873 . 4899204 . 0031-9384.
25. Idris . Iskandar . Coadministration of the long-acting amylin analog cagrilintide plus semaglutide (CagriSema), resulted in significantly greater weight loss, along with improved measures of glucose control, in a short phase 2 trial of patients with type 2 diabetes . Diabetes, Obesity and Metabolism Now . July 2023 . 1 . 7 . 10.1002/doi2.68 . 260221980 . 2688-8939. free .
26. Holst . Jens Juul . Jepsen . Sara Lind . Modvig . Ida . GLP-1 – Incretin and pleiotropic hormone with pharmacotherapy potential. Increasing secretion of endogenous GLP-1 for diabetes and obesity therapy . Current Opinion in Pharmacology . April 2022 . 63 . 102189 . 10.1016/j.coph.2022.102189. 35231672 . 247153792 . free .
27. Conceição-Furber . Ellen . Coskun . Tamer . Sloop . Kyle W. . Samms . Ricardo J. . Is Glucagon Receptor Activation the Thermogenic Solution for Treating Obesity? . Frontiers in Endocrinology . April 2022 . 13 . 868037 . 10.3389/fendo.2022.868037 . 35547006 . 9081793 . 1664-2392 . free .
28. Novikoff . Aaron . Müller . Timo D. . The molecular pharmacology of glucagon agonists in diabetes and obesity . Peptides . July 2023 . 165 . 171003 . 10.1016/j.peptides.2023.171003 . 36997003 . 10265134 . 0196-9781.
29. Yamada Y, Kato T, Ogino H, Ashina S, Kato K . Cetilistat (ATL-962), a novel pancreatic lipase inhibitor, ameliorates body weight gain and improves lipid profiles in rats . Hormone and Metabolic Research . 40 . 8 . 539–543 . August 2008 . 18500680 . 10.1055/s-2008-1076699 . 29076657 .
30. Web site: Orlistat (marketed as Alli and Xenical) Information . U.S. Food and Drug Administration . 8 July 2015 . 14 January 2024.
31. Web site: FDA Drug Safety Communication: Completed safety review of Xenical/Alli (orlistat) and severe liver injury. U.S. Food and Drug Administration (FDA). 16 December 2019. 24 April 2019. https://web.archive.org/web/20190424013003/https://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm213038.htm. live.
32. Kopelman P, Groot G, Rissanen A, Rossner S, Toubro S, Palmer R, Hallam R, Bryson A, Hickling RI . Weight loss, HbA1c reduction, and tolerability of cetilistat in a randomized, placebo-controlled phase 2 trial in obese diabetics: comparison with orlistat (Xenical) . Obesity . 18 . 1 . 108–115 . January 2010 . 19461584 . 10.1038/oby.2009.155 . 205526626 . free .
33. Pereira . Maria J. . Eriksson . Jan W. . Emerging Role of SGLT-2 Inhibitors for the Treatment of Obesity . Drugs . 2019 . 79 . 3 . 219–230 . 10.1007/s40265-019-1057-0 . 30701480 . 6394798 . 0012-6667 . free .
34. Parascandola J . Dinitrophenol and bioenergetics: an historical perspective . Molecular and Cellular Biochemistry . 5 . 1–2 . 69–77 . November 1974 . 4610359 . 10.1007/BF01874175 . 2656970 .
35. Book: Swann . John P. . Perspectives on Twentieth-century Pharmaceuticals . 2010 . Peter Lang . 978-3-03910-920-3 . 289, 292, 299, 301 . Reducing with dinitrophenol : self-medication, and the challenge of regulating a dangerous pharmaceutical before the US Food, Drug, and Cosmetic Act.
36. Cohen PA, Goday A, Swann JP . The return of rainbow diet pills . American Journal of Public Health . 102 . 9 . 1676–1686 . September 2012 . 22813089 . 3482033 . 10.2105/AJPH.2012.300655 .
37. Setola . Vincent . Roth . Bryan L . Screening the receptorome reveals molecular targets responsible for drug-induced side effects: focus on 'fen–phen' . Expert Opinion on Drug Metabolism & Toxicology . October 2005 . 1 . 3 . 377–387 . 10.1517/17425255.1.3.377. 16863450 . 30930020 .
38. Book: Pool, Robert . Fat: Fighting the Obesity Epidemic . Oxford University Press . Oxford, UK . 2001 . 978-0-19-511853-7 . registration .
39. Lafferty . Ryan A. . Flatt . Peter R. . Irwin . Nigel . GLP-1/GIP analogs: potential impact in the landscape of obesity pharmacotherapy . Expert Opinion on Pharmacotherapy . March 2023 . 24 . 5 . 587–597 . 10.1080/14656566.2023.2192865. 36927378 . 257580812 . free .
40. News: GLP-1 receptor agonists: Breaking down the hype and demand . 1 November 2023 . American Pharmacists Association . 1 November 2023 . https://web.archive.org/web/20231101032838/https://www.pharmacist.com/Publications/Pharmacy-Today/Article/glp-1-receptor-agonists-breaking-down-the-hype-and-demand . live .
41. Web site: Colman E . February 2007 . Guidance for Industry Developing Products for Weight Management . . 19 July 2022 . 13 October 2022 . https://web.archive.org/web/20221013073226/http://www.fda.gov/media/71252/download . live .
42. Web site: Wegovy . European Medicines Agency . 3 November 2023 . 11 November 2021 . 2 July 2022 . https://web.archive.org/web/20220702222728/https://www.ema.europa.eu/en/medicines/human/EPAR/wegovy#:~:text=Wegovy%20is%20effective%20at%20reducing,side%20effects%20are%20considered%20manageable. . live .
43. News: A major medical group updated its guidance for treating childhood obesity. Here's what it says. . 1 November 2023 . NBC News . 9 January 2023 . 1 November 2023 . https://web.archive.org/web/20231101025413/https://www.nbcnews.com/health/kids-health/new-guidelines-treating-childhood-obesity-include-medications-surgery-rcna64651 . live .
44. News: European Medicines Agency recommends weight loss drug Wegovy for teenagers 12 and up . 1 November 2023 . Diabetes . 1 November 2023 . https://web.archive.org/web/20231101025414/https://www.diabetes.co.uk/news/2023/apr/european-medicines-agency-recommends-weight-loss-drug-wegovy-for-teenagers-12-and-up.html . live .
45. Web site: Latest Obesity Drug Not Cost-Effective for Adolescents . Columbia University Irving Medical Center . 1 November 2023 . 12 September 2023 . 1 November 2023 . https://web.archive.org/web/20231101025415/https://www.cuimc.columbia.edu/news/latest-obesity-drug-not-cost-effective-adolescents . live .
46. 21 June 2021 . FDA Approves New Drug Treatment for Chronic Weight Management, First Since 2014 . 19 July 2022 . U.S. Food and Drug Administration (FDA) . 4 June 2021 . https://web.archive.org/web/20210604235421/https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-treatment-chronic-weight-management-first-2014 . live .
47. Haslam . D. . Weight management in obesity – past and present . International Journal of Clinical Practice . March 2016 . 70 . 3 . 206–217 . 10.1111/ijcp.12771 . 26811245 . 4832440 . 1368-5031.
48. Web site: Obesity Medication: Gastrointestinal Agents, Other, CNS Stimulants, Anorexiants, Glucagon-like Peptide-1 Agonists, Antidepressants, dopamine reuptake inhibitors; opioid antagonists. emedicine.medscape.com. 2 November 2016. 4 November 2016. https://web.archive.org/web/20161104011650/http://emedicine.medscape.com/article/123702-medication. live.
49. Müller . Timo D. . Blüher . Matthias . Tschöp . Matthias H. . DiMarchi . Richard D. . Anti-obesity drug discovery: advances and challenges . Nature Reviews Drug Discovery . March 2022 . 21 . 3 . 201–223 . 10.1038/s41573-021-00337-8 . 34815532 . 8609996 .
50. Wilding JP, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J, Tran MT, Wadden TA, Wharton S, Yokote K, Zeuthen N, Kushner RF . Once-Weekly Semaglutide in Adults with Overweight or Obesity . The New England Journal of Medicine . 384 . 11 . 989–1002 . March 2021 . 33567185 . 10.1056/NEJMoa2032183 . 231883214 . 21 February 2023 . 18 March 2023 . https://web.archive.org/web/20230318145219/https://discovery.ucl.ac.uk/id/eprint/10127569/ . live . free .
51. Web site: 13 June 2013 . Qsiva . European Medicines Agency (EMA) . 12 December 2022 . 12 December 2022 . https://web.archive.org/web/20221212222154/https://www.ema.europa.eu/en/medicines/human/EPAR/qsiva . live .
52. Smith SM, Meyer M, Trinkley KE . Phentermine/topiramate for the treatment of obesity . The Annals of Pharmacotherapy . 47 . 3 . 340–349 . March 2013 . 23482732 . 10.1345/aph.1R501 . 30461611 .
53. Lei . Xiang-Guo . Ruan . Jia-Qi . Lai . Chen . Sun . Ziyi . Yang . Xi . Efficacy and Safety of Phentermine/Topiramate in Adults with Overweight or Obesity: A Systematic Review and Meta-Analysis . Obesity . June 2021 . 29 . 6 . 985–994 . 10.1002/oby.23152 . 33864346 . 233278420 .
54. Web site: Mysimba EPAR . European Medicines Agency (EMA) . 17 September 2018 . 5 August 2020 . 22 October 2020 . https://web.archive.org/web/20201022220427/https://www.ema.europa.eu/en/medicines/human/EPAR/mysimba . live .
55. Alruwaili . Heshma . Dehestani . Babak . le Roux . Carel W . Clinical Impact of Liraglutide as a Treatment of Obesity . Clinical Pharmacology: Advances and Applications . March 2021 . 13 . 53–60 . 10.2147/CPAA.S276085 . 33732030 . 7958997 . 1179-1438 . free .
56. Grunvald . E . Shah . R . Hernaez . R . Chandar . AK . Pickett-Blakely . O . Teigen . LM . Harindhanavudhi . T . Sultan . S . Singh . S . Davitkov . P . AGA Clinical Guidelines . Committee . AGA Clinical Practice Guideline on Pharmacological Interventions for Adults With Obesity. . Gastroenterology . November 2022 . 163 . 5 . 1198–1225 . 10.1053/j.gastro.2022.08.045 . 36273831. 253052479 . free .
57. Greenway FL, Aronne LJ, Raben A, Astrup A, Apovian CM, Hill JO, Kaplan LM, Fujioka K, Matejkova E, Svacina S, Luzi L, Gnessi L, Navas-Carretero S, Alfredo Martinez J, Still CD, Sannino A, Saponaro C, Demitri C, Urban LE, Leider H, Chiquette E, Ron ES, Zohar Y, Heshmati HM . A Randomized, Double-Blind, Placebo-Controlled Study of Gelesis100: A Novel Nonsystemic Oral Hydrogel for Weight Loss . Obesity . 27 . 2 . 205–216 . February 2019 . 30421844 . 6587502 . 10.1002/oby.22347 .
58. Padwal RS, Majumdar SR . Drug treatments for obesity: orlistat, sibutramine, and rimonabant . Lancet . 369 . 9555 . 71–77 . January 2007 . 17208644 . 10.1016/S0140-6736(07)60033-6 . 35104831 .
59. Kim . Kyoung Kon . Cho . Hi-Jung . Kang . Hee-Cheol . Youn . Bang-Bu . Lee . Kyu-Rae . Effects on Weight Reduction and Safety of Short-Term Phentermine Administration in Korean Obese People . Yonsei Medical Journal . October 2006 . 47 . 5 . 614–625 . 10.3349/ymj.2006.47.5.614 . 17066505 . 2687747 . 0513-5796.
60. Web site: 8 November 2023 . FDA Approves Lilly's Zepbound™ (tirzepatide) for Chronic Weight Management, a Powerful New Option for the Treatment of Obesity or Overweight with Weight-Related Medical Problems . 13 November 2023 . investor.lilly.com/ . 13 November 2023 . https://web.archive.org/web/20231113065428/https://investor.lilly.com/news-releases/news-release-details/fda-approves-lillys-zepboundtm-tirzepatide-chronic-weight . live .
61. News: EU regulator recommends Eli Lilly's Mounjaro for weight management . 16 November 2023 . Reuters . 10 November 2023 . 16 November 2023 . https://web.archive.org/web/20231116012351/https://www.reuters.com/business/healthcare-pharmaceuticals/eu-regulator-backs-eli-lillys-mounjaro-weight-management-2023-11-10/. live .
62. Lin . Fei . Yu . Bin . Ling . Baodong . Lv . Guangyao . Shang . Huijun . Zhao . Xia . Jie . Xiaoling . Chen . Jing . Li . Yan . Weight loss efficiency and safety of tirzepatide: A Systematic review . PLOS ONE . 18 . 5 . 4 May 2023 . 1932-6203 . 37141329 . 10159347 . 10.1371/journal.pone.0285197 . free . e0285197 . 2023PLoSO..1885197L . Over all, meta-analysis showed a significant reduction in body weight in the tirzepatide group versus the placebo group by -9.81 kg (95% CI (-12.09, -7.52). There were three doses investigated compared to the placebo group were affected significantly reduced the body weight of patients [5 mg: MD = -7.52 kg, 95% CI (-10.86, -4.18), P < 0.0001; I2 = 94%; 10 mg: MD = -10.48 kg, 95% CI (-15.34, -5.62), P < 0.0001; I2 = 97%; 15 mg: MD = -10.91 kg, 95% CI (-14.81, -7.01), P < 0.00001; I2 = 96%].
63. Tuccinardi . Dario . Farr . Olivia M. . Upadhyay . Jagriti . Oussaada . Sabrina M. . Mathew . Hannah . Paschou . Stavroula A. . Perakakis . Nikolaos . Koniaris . Anastasia . Kelesidis . Theodoros . Mantzoros . Christos S. . Lorcaserin treatment decreases body weight and improves cardiometabolic risk factors of obese adults: A 6-month-long, randomized, placebo-controlled, double-blind clinical trial. . Diabetes, Obesity & Metabolism . June 2019 . 21 . 6 . 1487–1492 . 10.1111/dom.13655 . 30724455 . 6504613 . 1462-8902.
64. Web site: Meridia (sibutramine): Market Withdrawal Due to Risk of Serious Cardiovascular Events. . 16 December 2019. 18 January 2017. https://web.archive.org/web/20170118093659/http://www.fda.gov/safety/medwatch/safetyinformation/safetyalertsforhumanmedicalproducts/ucm228830.htm. live.
65. Web site: 23 October 2012 . Recalls and safety alerts . live . https://web.archive.org/web/20201023051149/https://www.healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2010/10058r-eng.php . 23 October 2020 . 31 August 2020 . Health Canada . Government of Canada.
66. Dedov . Ivan Ivanovich . Melnichenko . Galina Afanasievna . Troshina . Ekaterina Anatolievna . Mazurina . Natalya Valentinovna . Galieva . Marina Olegovna . Body Weight Reduction Associated with the Sibutramine Treatment: Overall Results of the PRIMAVERA Primary Health Care Trial . Obesity Facts . September 2018 . 11 . 4 . 335–343 . 10.1159/000488880 . 30089303 . 6189539 . 1662-4025.
67. Christopoulou . F. D. . Kiortsis . D. N. . An overview of the metabolic effects of rimonabant in randomized controlled trials: potential for other cannabinoid 1 receptor blockers in obesity: The metabolic effects of rimonabant . Journal of Clinical Pharmacy and Therapeutics . February 2011 . 36 . 1 . 10–18 . 10.1111/j.1365-2710.2010.01164.x . 21198716 . 3274949 . free .
68. Wadden . T. A. . Berkowitz . R. I. . Silvestry . F. . Vogt . R. A. . St John Sutton . M. G. . Stunkard . A. J. . Foster . G. D. . Aber . J. L. . The fen-phen finale: a study of weight loss and valvular heart disease . Obesity Research . July 1998 . 6 . 4 . 278–284 . 10.1002/j.1550-8528.1998.tb00350.x . 9688104 . 1071-7323. free .
69. Davis . Rick . Faulds . Diana . Dexfenfluramine . Drugs . November 1996 . 52 . 5 . 696–724 . 10.2165/00003495-199652050-00007 . 9118819 . 195698330 .
70. Tainter . M. L. . Dinitrophenol in the Treatment of Obesity: Final Report . Journal of the American Medical Association . August 1935 . 105 . 5 . 332 . 10.1001/jama.1935.02760310006002.
71. Web site: Role of OTC Asthma Medications in the Community Pharmacy . Pharmacy Times . 24 October 2023 . 8 December 2021 . 19 February 2023 . https://web.archive.org/web/20230219010658/https://www.pharmacytimes.com/view/role-of-otc-asthma-medications-in-the-community-pharmacy . live .
72. Yoo . Hee-Jeong . Yoon . Ha-Young . Yee . Jeong . Gwak . Hye-Sun . Effects of Ephedrine-Containing Products on Weight Loss and Lipid Profiles: A Systematic Review and Meta-Analysis of Randomized Controlled Trials . Pharmaceuticals . November 2021 . 14 . 11 . 1198 . 10.3390/ph14111198 . 34832979 . 8618781 . 1424-8247 . free .
73. Book: Eckerson . Joan M. . Nutritional Supplements in Sports and Exercise . 2015 . Springer International Publishing . 978-3-319-18230-8 . 159–185 . https://link.springer.com/chapter/10.1007/978-3-319-18230-8_8 . Weight Loss Nutritional Supplements . 10.1007/978-3-319-18230-8_8 . 24 October 2023 . 2 November 2023 . https://web.archive.org/web/20231102060326/https://link.springer.com/chapter/10.1007/978-3-319-18230-8_8 . live .
74. Schteingart . D. E. . Effectiveness of phenylpropanolamine in the management of moderate obesity . International Journal of Obesity and Related Metabolic Disorders: Journal of the International Association for the Study of Obesity . July 1992 . 16 . 7 . 487–493 . 1323545 .
75. Jastreboff AM, Kaplan LM, Frías JP, Wu Q, Du Y, Gurbuz S, Coskun T, Haupt A, Milicevic Z, Hartman ML . Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial . The New England Journal of Medicine . June 2023 . 389 . 6 . 514–526 . 37366315 . 10.1056/NEJMoa2301972. 259260926 . Free access subject to registration.
76. Dushay . Jody . Gao . Chuanyun . Gopalakrishnan . Gosala S. . Crawley . Meghan . Mitten . Emilie K. . Wilker . Elissa . Mullington . Janet . Maratos-Flier . Eleftheria . Short-Term Exenatide Treatment Leads to Significant Weight Loss in a Subset of Obese Women Without Diabetes . Diabetes Care . January 2012 . 35 . 1 . 4–11 . 10.2337/dc11-0931 . 22040840 . 3241299 . 0149-5992.
77. Kopelman . Peter . Groot . Gerrit de H. . Rissanen . Aila . Rossner . Stephan . Toubro . Soren . Palmer . Richard . Hallam . Rob . Bryson . Andrew . Hickling . Roger I. . Weight loss, HbA1c reduction, and tolerability of cetilistat in a randomized, placebo-controlled phase 2 trial in obese diabetics: comparison with orlistat (Xenical) . Obesity (Silver Spring) . January 2010 . 18 . 1 . 108–115 . 10.1038/oby.2009.155 . 19461584 . 205526626 .
78. Axel . Anne Marie D . Mikkelsen . Jens D . Hansen . Henrik H . Tesofensine, a Novel Triple Monoamine Reuptake Inhibitor, Induces Appetite Suppression by Indirect Stimulation of α1 Adrenoceptor and Dopamine D1 Receptor Pathways in the Diet-Induced Obese Rat . Neuropsychopharmacology . June 2010 . 35 . 7 . 1464–1476 . 10.1038/npp.2010.16 . 20200509 . 3055463 . 0893-133X.
79. Seifarth . C. . Schehler . B. . Schneider . H. J. . Effectiveness of metformin on weight loss in non-diabetic individuals with obesity . Experimental and Clinical Endocrinology & Diabetes . January 2013 . 121 . 1 . 27–31 . 10.1055/s-0032-1327734 . 23147210 . 20506527 . 1439-3646. free .
80. Lau . David C W . Erichsen . Lars . Francisco . Ann Marie . Satylganova . Altynai . le Roux . Carel W . McGowan . Barbara . Pedersen . Sue D . Pietiläinen . Kirsi H . Rubino . Domenica . Batterham . Rachel L . Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial . The Lancet . December 2021 . 398 . 10317 . 2160–2172 . 10.1016/S0140-6736(21)01751-7 . 34798060 . 244169045 .
81. Web site: Bachorik L . FDA Announces Withdrawal Fenfluramine and Dexfenfluramine (Fen-Phen) . U.S. Food and Drug Administration . U.S. Food and Drug Administration (FDA). 27 January 2014. 4 November 2009. https://web.archive.org/web/20091104225047/https://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm179871.htm. live.
82. Onakpoya . Igho J. . Heneghan . Carl J. . Aronson . Jeffrey K. . 2016 . Post-marketing withdrawal of anti-obesity medicinal products because of adverse drug reactions: a systematic review . BMC Medicine . 14 . 1 . 191 . 10.1186/s12916-016-0735-y . 1741-7015 . 5126837 . 27894343 . free .
83. Book: Kolata, Gina . Rethinking thin: The new science of weight loss – and the myths and realities of dieting . Picador . 2007 . 978-0-312-42785-6.